Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

82 results about "Distant metastasis" patented technology

Distant metastasis. listen (DIS-tunt meh-TAS-tuh-sis) Refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.

Method for establishing nasopharyngeal carcinoma distant metastasis predicting model

The invention discloses a method for establishing a nasopharyngeal carcinoma distant metastasis predicting model. The method comprises the steps of selecting a nasopharyngeal carcinoma tumor pathological slice digital image with known metastasis information as a training set of a deep learning algorithm; obtaining a processed nasopharyngeal carcinoma tumor pathological slice digital image; training and optimizing the processed nasopharyngeal carcinoma tumor pathological slice digital image and patient clinical information; establishing a function relation formula between a distant metastasis risk of a nasopharyngeal carcinoma patient and a score S, and performing interval classification on a P value with distant metastasis and the P value without distant metastasis. The invention providesthe method for establishing the nasopharyngeal carcinoma distant metastasis predicting model, wherein a deep learning algorithm is applied in pathology, and artificial intelligence technology is utilized for realizing establishment of a tumor prognosis predicting model.
Owner:TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL +2

Nasopharyngeal carcinoma distant metastasis predicting system based on deep learning algorithm

The invention discloses a nasopharyngeal carcinoma distant metastasis predicting system based on a deep learning algorithm. The predicting system comprises the following modules of: an image acquisition module, an image preprocessing module, a patient information collecting module, a distant metastasis predicting module based on the deep learning algorithm, and a predicting information output module. The system of the invention realizes risk predicting to nasopharyngeal carcinoma distant metastasis of a nasopharyngeal carcinoma patient. Compared with an analysis-diagnosis-treatment mode in which traditional molecular biological technology and gene sequencing and the like are used as main means, the system has advantages of improving efficiency in acquiring a diagnosis result and realizingpredictive judgment which cannot be independently performed by a clinical doctor.
Owner:TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL +2

Biomarker reagent used for detecting breast cancer state

The invention discloses a biomarker reagent used for detecting a breast cancer state, which is an ultra high resolution fracsimile (UHRF 1) gene. The UHRF 1 gene is closely related to distant metastasis capacity of a breast cancer; the UHRF 1 gene is used as a biomarker predicting the distant metastasis capacity of the breast cancer, and the malignancy degree of the breast cancer can be predicted more accurately in a more individualized manner compared with transferring and prognosis of the breast cancer judged by the conventional pathological type.
Owner:SUZHOU UNIV

ELISA (enzyme linked immunosorbent assay) kit for detecting endothelial cell specific molecule-1 (ESM-1) of tumour marker

The invention provides an ELISA (enzyme linked immunosorbent assay) kit for detecting endothelial cell specific molecule-1 (ESM-1) of a tumour marker, wherein the kit comprises (1) a coated antibody, wherein the coated antibody is a mouse anti-human ESM-1 antibody; (2) a detection antibody, wherein the detection antibody is a biotinylated goat anti-human Endocan antibody; (3) an enzyme linked antibody, wherein the enzyme liked antibody is a rabbit anti-goat IgG (immunoglobulin G) marked by a horseradish peroxidase; (4) a human Endocan standard substance; and (5) a colour development substrate of the enzyme linked antibody. By the kit provided by the invention, the early diagnosis rate of gastric cancer can be improved under a relatively small wound; the biomarker is an independent prognostic factor and is relevant to vessel invasion, distant metastasis and general classification of gastric cancer, so that prognosis can be predicted, states of the illness can be monitored, and treatments can be guided.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Application of esophageal squamous cell carcinoma primary tumor line CH-H-2

InactiveCN102766600AStable traitsHigh metastatic potentialTumor/cancer cellsPrimary tumorBasic research
The invention relates to an esophageal squamous cell carcinoma primary tumor line CH-H-2 which is used in mammals to produce esophageal squamous cell carcinoma cells. The primary tumor line CH-H-2 can be passed by NOD / SCID mice for multiple times, is significant in solving the inevitable bottleneck problem of distant metastasis in the current esophageal squamous cell carcinoma treatment, and is an ideal object for the basic research and clinical early application of esophageal squamous cell carcinoma.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

A molecular marker for esophageal cancer and uses thereof

A molecular marker for esophageal cancer is disclosed and is an FXR1 gene and / or an expression product of the FXR1 gene. The FXR1 gene is significantly highly expressed in esophageal cancer tissue, and can be adopted as an esophageal cancer molecular marker for esophageal cancer diagnosis. The highly expressed FXR1 gene is closely related to poor prognosis and distant metastasis of patients with esophageal cancer so that the FXR1 gene can be adopted as a prognosis marker for esophageal cancer and can provide effective information for esophageal cancer distant metastasis, prognosis evaluation and treatment effect monitoring. An expression inhibitor of the FXR1 gene is disclosed by the invention and includes siRNA and / or shRNA, has good jamming effects when being used for suppressing FXR1 gene expression and has a potential for application in clinical genetic treatment. The invention further discloses a cell strain capable of stable knock-down of the FXR1 gene. The cell strain is an esophageal cancer cell capable of stable low expression of the FXR1 gene, thus facilitating further research of functions of the FXR1 gene.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV

Hollow gold nanospheres modified by CpG oligodeoxynucleotide as well as preparation method and applications

The invention discloses a preparation method and applications of hollow gold nanospheres modified by CpG oligodeoxynucleotide. Cobalt chloride is subjected to reduction by adopting sodium borohydride,thus cobalt nanoparticles are obtained, cobalt nanoparticles are adopted for carrying out reduction on chloroauric acid, and thus hollow gold nanospheres are prepared; CpG oligodeoxynucleotide, a surfactant and a buffer solution are added into a solution of the hollow gold nanospheres, shaking culture is carried out, and thus the hollow gold nanosphere material modified by CpG oligodeoxynucleotide is obtained. According to the technical scheme, by utilizing the property that the hollow gold nanospheres have the large loading capacity, CpG is loaded through the self-assembly effect, the synthesis method is simple, and the method is suitable for large-scale production and application; the cell uptake capacity of CpG oligodeoxynucleotide can be enhanced, and the biocompatibility is good; thehollow gold nanospheres modified by CpG oligodeoxynucleotide have the near-infrared surface plasma adsorbing effect, the primary tumor is eliminated by utilizing the photothermal ablation effect, a tumor antigen is generated in situ, under the promoting of CpG oligodeoxynucleotide, the antitumor immunity of the whole body is induced, and the distant metastasis tumor is further treated.
Owner:WUHAN UNIV OF SCI & TECH

64Cu labeled PSMA targeted inhibitor as well as preparation method and application thereofCu

The invention provides a novel 64Cu labeled PSMA targeted inhibitor as well as a preparation method and an application thereof. The 64Cu labeled PSMA targeted inhibitor is a 64Cu labeled NODA-PSMA conjugate; the inhibitor, when used as a prostate PET molecular probe, is good in stability and good in developing effect; the inhibitor is conducive to diagnosis and accurate staging of early prostate and is beneficial for guiding surgical resection; and the inhibitor can offer a diagnosis basis for recurrence as well as local and distant metastasis of the prostate; therefore, the inhibitor has an important clinical application value.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Tyrosine kinase inhibitor and application thereof

The invention discloses a tyrosine kinase inhibitor. A chemical name of the tyrosine kinase inhibitor is 1-(2-chloro-4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-3-(4-fluorophenyl)carbamide and a structure is shown as a formula (I). Meanwhile, the invention further discloses application of the tyrosine kinase inhibitor. The tyrosine kinase inhibitor provided by the invention can be used for effectively inhibiting enzymatic activity of VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) and VEGFR3 (Vascular Endothelial Growth Factor Receptor 3) and can be used for effectively treating diseases which are regulated and controlled through tyrosine kinase and are related with anomaly of a tyrosine kinase signal transduction pathway, and the diseases comprise cancers of breasts, respiratory tracts, brains, reproductive organs, digestive tracts, urinary tracts, eyes, livers, skin, heads and / or necks and distant metastasis of the cancers, lymphoma, sarcoma, leukemia and the like.
Owner:GUANGZHOU LIUSHUN BIO TEC CO LTD +1

Storing and recording method and classified collecting box for organ specimens and lymph node specimens in surgical operations

The invention relates to the field of medical treatment, in particular to a storing and recording method and classified collecting box for organ specimens and lymph node specimens in surgical operations. The classified collecting box for the organ specimens and the lymph node specimens in the surgical operations comprises a classification box I and a classification box II. The upper surface of the classification box I is divided into a primary lesion storing area and a distant metastasis storing area. An organ specimen storing tank is arranged in the primary lesion storing area. An anatomical atlas is arranged on the upper surface of the classification box II, and a plurality of lymph node specimen storing tanks are formed in the upper surface of the classification box II. The storing and recording method for the organ specimens and the lymph node specimens in the surgical operations comprises the steps that the classified collecting box for the organ specimens and the lymph node specimens in the surgical operations is adopted; and taken-down distant metastasis tissue is placed into distant metastasis storing tanks, then corresponding marks are pasted to the positions near the distant metastasis storing tanks, and the specific sampling positions of the distant metastasis tissue in corresponding sampling organs are marked on mark pasters. Comprehensive and detailed recording can be carried out on related information of the specimens in the surgical operations.
Owner:王洛 +1

Cancer marker and use thereof

The invention discloses a cancer marker, wherein the cancer is a prostate cancer, and the cancer marker is an expression product of an APMAP gene and / or an APMAP gene. The APMAP gene is highly expressed in prostate cancer, which can be used for early diagnosis of prostate cancer, and has the advantages of specificity and high sensitivity. The high expression of APMAP gene is closely related to thepoor prognosis, distant metastasis and lymph node metastasis of prostate cancer, suggesting that APMAP gene can be used as a prognostic marker to provide effective information for the metastasis diagnosis, prognosis evaluation and treatment effect monitoring of prostate cancer. The invention discloses an expression inhibitor of an APMAP gene, comprising siRNA and / or shRNA, which has good interference effect on the expression of the APMAP gene, and has the application potential of clinical gene therapy. The invention discloses a cell strain of stable knockdown APMAP gene, which is favorable for realizing further research on gene function.
Owner:SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI

CircPTEN1 for tumor treatment target and diagnosis biomarker and application of circPTEN1

The invention provides circPTEN1 for a tumor treatment target and a diagnosis biomarker and application of circPTEN1, and belongs to the technical field of biology. A nucleotide sequence of the circPTEN1 for the tumor treatment target and the diagnosis biomarker is shown as SEQ ID NO: 1, and the circPTEN1 is a novel circular RNA formed by reversely splicing the first exon to the fifth exon of PTEN mRNA. High expression of the circPTEN1 remarkably inhibits migration and invasion of colorectal cancer cells, the expression level of the circPTEN1 is in negative correlation with lymph node metastasis and distant metastasis of a colorectal cancer patient, and prognosis of the colorectal cancer patient with low expression of the circPTEN1 is poor. Therefore, the circPTEN1 is applied to tumor treatment, tumor diagnosis and tumor prognosis evaluation as the tumor treatment target and the diagnostic biomarker, and a new thought and a new strategy are provided for treatment-related drugs and diagnostic products.
Owner:PEKING UNIV

Lung cancer TNM staging acquisition method and device, and display method

The invention discloses a lung cancer TNM staging acquisition method. The method comprises the following steps of identifying a target nodule in a medical image; acquiring long and short paths of thetarget nodule, and generating T stages at least based on the long and short path; identifying abnormal lymph nodes in the medical image, and generating N stages by judging whether the abnormal lymph nodes have metastasis or not; acquiring whether the target nodule has distant metastasis or not, and generating M stages according to whether the target nodule has distant metastasis or not; and generating a TNM stage according to the T stage, the N stage and the M stage. According to the method, a nodule recognition model, a nodule segmentation model and a lymph node metastasis recognition model are trained, the information outputted by the models is utilized to automatically generate a T stage and an N stage, and whether distant metastasis information is generated into an M stage or not is judged in combination with doctor input or by accessing medical records and the like. According to the method, TNM staging generation efficiency is effectively improved, a doctor can conveniently and quickly know the illness state of a patient, and diagnosis efficiency is improved.
Owner:HANGZHOU YITU MEDIAL TECH CO LTD

Papillary thyroid carcinoma distant metastasis mutation predicting model, method and system

The invention provides a papillary thyroid carcinoma distant metastasis mutation predicting model, a predicting model method and a predicting model system. The papillary thyroid carcinoma distant metastasis mutation predicting model realizes high predicting accuracy which is higher than that of a currently reported model. Furthermore the papillary thyroid carcinoma distant metastasis mutation predicting model has high sensitivity and high specificity. Furthermore researching of the invention proves a fact that TERT starter mutation has no evident correlation with distant metastasis, and furthermore chr22q loss and gene fusion are remarkably correlated with distant metastasis. The samples of the invention are obtained from Chinese people, and foreign researching samples are obtained from the Western country people. Therefore the researching result of the invention has higher application value for the Chinese people.
Owner:ZHEJIANG CANCER HOSPITAL

Medical information processing method and system and storage medium

The invention relates to a medical information processing method. The method comprises the steps: obtaining first to third recognition information based on the AI recognition of first medical information, second medical information and third medical information, wherein the first recognition information comprises the tumor primary lesion condition, the second recognition information comprises theregional lymph node fatigue condition, and the third identification information comprises a remote transfer condition; and outputting interpretation information according to the first recognition information, the second recognition information, the third recognition information and standard information. The medical information processing system is linked to a medical diagnosis business data systemthrough a corresponding data interface, and comprises: an AI identification module configured to obtain identification information including different pathological information based on different medical information, and an analysis module used for obtaining the interpretation information according to the different identification information and the standard information. Through the embodiments ofthe invention, intelligent inference of corresponding diagnosis information can be realized, the working efficiency of doctors is improved, and the clinical data preparation cost is reduced.
Owner:HANGZHOU YITU MEDIAL TECH CO LTD

Genetic markers and methods for detecting and treating cancers

The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient, evaluating the expression levels of the SOX5 and / or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue. Furthermore, the identified genetic marker SOX5 and / or SPARC can also be used for cancer targeted therapy, because down regulation of SOX5 and / or up regulation of SPARC expression in NOD-SCID can retard tumor growth and inhibit cell proliferation, migration, invasion and metastasis.
Owner:NAT TAIWAN UNIV

Intestinal cancer peritoneal metastasis prediction model and construction method thereof

The invention relates to the field of biomedicine. More specifically, the present invention relates to an intestinal cancer peritoneal metastasis prediction model and a construction method thereof. The intestinal cancer peritoneal metastasis prediction model is as follows: Model=32.892 + 1.51 * CT_stage + 1.884*tumor location + 20.447*distant metastatic sites - 19.898*thickened greater omentum - 20.222*pelvic nodules, wherein the CT_stage is a T stage, the tumor location is a tumor site, the tumor location is a tumor site, the distant metastatic sites are used as far transfer parts, the thickened greater omentum is used for thickening the omentum majus, and the pelvic nodules are pelvic implant nodules. The intestinal cancer peritoneal metastasis prediction model is high in prediction accuracy and has high sensitivity and specificity.
Owner:THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Method for enhancing high intensity focused ultrasound (HIFU) induced anti-tumor immune response

InactiveCN101898012ADoes not affect the effect of thermal ablation therapyGood treatment effectUltrasound therapyAbnormal tissue growthSonification
The invention belongs to the medical technology field, in particular relating to a method for enhancing high intensity focused ultrasound (HIFU) induced anti-tumor immune response. On the premise of having no change on the existing HIFU oncotherapy ultrasound strength, the method utilizes a sparse scanning strategy to enable tumor tissue heat denaturation spots generated by single HIFU treatment to have a proper spacing so as to reserve tissues around each heat denaturation area. The method can enable the tumor issues to have stronger capacity of recruiting and activating interdigitate cells and inducing out stronger anti-tumor immune response while having no influence on primary tumor thermal ablation curative effect by HIFU, thus killing epibiotic viable cells and preventing and curing tumour distant metastases. The method can improve overall tumor curative effect of HIFU and shorten curative time.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Tyrosine kinase inhibitor and application thereof

The invention discloses a tyrosine kinase inhibitor. A chemical name of the tyrosine kinase inhibitor is 1-(2-chloro-4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-3-(4-fluorophenyl)carbamide and a structure is shown as a formula (I). Meanwhile, the invention further discloses application of the tyrosine kinase inhibitor. The tyrosine kinase inhibitor provided by the invention can be used for effectively inhibiting enzymatic activity of VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) and VEGFR3 (Vascular Endothelial Growth Factor Receptor 3) and can be used for effectively treating diseases which are regulated and controlled through tyrosine kinase and are related with anomaly of a tyrosine kinase signal transduction pathway, and the diseases comprise cancers of breasts, respiratory tracts, brains, reproductive organs, digestive tracts, urinary tracts, eyes, livers, skin, heads and / or necks and distant metastasis of the cancers, lymphoma, sarcoma, leukemia and the like.
Owner:GUANGZHOU LIUSHUN BIO TEC CO LTD +1

Novel target PCDHB2 for breast cancer osseous metastasis diagnosis and treatment

The invention discloses a novel target PCDHB2 for breast cancer osseous metastasis diagnosis and treatment. The significantly high expression of the PCDHB2 in multiple subtype breast cancer tissue with the osseous metastasis is determined, the high expression of the PCDHB2 in all kinds of breast cancer tissue, BasL breast cancer tissue and other types (LumA type, Lumb type and Her2 type) of breastcancer tissue indicates the occurrence of earlier osseous metastasis, the PCDHB2 is not associated with distant metastasis of other parts of the breast cancer (brain, lung and liver), and it is suggested that the PCDHB2 can more specifically predict the occurrence of the breast cancer osseous metastasis. The down-regulation of PCDHB2 expression can significantly inhibit osseous metastasis of breast cancer cells and inhibit anoikis, migration and invasion resisting capacities of the breast cancer cells, and the PCDHB2 is the novel target of diagnosis, prognosis and treatment of breast cancer osseous metastasis.
Owner:江门市中心医院

Lung cancer TNM staging acquisition method and device

PendingCN112488993AImprove production efficiencyQuickly understand the conditionImage enhancementMedical data miningLung cancer stagingTARGET NODULE
The invention discloses a lung cancer TNM staging acquisition method and device. The method includes identifying a first target nodule in a first medical image; matching the first target nodule in a second medical image, and obtaining a second target nodule in the second medical image; acquiring long and short diameters of the second target nodule, and generating T stages at least according to thelong and short diameters of the second target nodule; identifying abnormal lymph nodes in the first medical image and generating N stages by judging whether the abnormal lymph nodes have metastasis or not; identifying whether the first target nodule in the first medical image has distant metastasis or not, and generating M stages according to whether the first target nodule has distant metastasisor not; and generating a TNM stage according to the T stage, the N stage and the M stage; wherein the first medical image and the second medical image are different modal medical images for the samepatient and the same part. According to the scheme, the TNM staging generation efficiency is effectively improved, doctors can conveniently and quickly know the illness state of a patient, and the diagnosis efficiency is improved.
Owner:HANGZHOU YITU MEDIAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products